PD-1 expression on the tumor-specific T cells following anti-CTLA-4 alone or dual therapy remained slightly elevated in the tumor compared to the spleen 14 days after treatment (Fig. 6h; Supplementary Fig. 4a). This evidence concerns the gene PDCD1 and neoplasm.